GSKGlaxoSmithKlineSigning up patients
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 800 (planned)
- Started
- Jul 27, 2026
- Main results expected
- Aug 30, 2032
- Fully finished
- Sep 28, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)
Measured over: Up to approximately 74 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07585266 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC